Clinical Trials · NCT01809691
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- SWOG Cancer Research Network
- Enrollment
- 1,313
- Start date
- Mar 2013
- Locations
- 560 sites, United States
- Primary endpoint
- Overall Survival